Mode
Text Size
Log in / Sign up
N/A N=130 Randomized Other

Trial of Self-managed Approaches for Patellofemoral Pain Syndrome in Active Duty

Patellofemoral Pain Syndrome

Enrolled (actual)
130
Serious AEs
0.0%
Results posted
Oct 2020
Primary outcome: Primary: Lower Extremity Muscle Strength- Extension — 41.58; 37.74; 37.14; 40.42 Kg-Force

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Home Exercise Program (HEP) (Other); NMES (Device); TENS (Device)
Age
Adult · 18+ yrs
Sex
All
Sponsor
University of Tennessee
Primary completion
May 2018

Outcome Measures

OutcomeResultp-value
PRIMARY
Lower Extremity Muscle Strength- Extension
41.58; 37.74; 37.14; 40.42; 41.41; 42.70
PRIMARY
Lower Extremity Muscle Strength- Flexion
21.85; 20.32; 21.33; 21.95; 22.07; 22.49
PRIMARY
Lower Extremity Strength- 30-Second Chair Stand Test
11.6; 11.0; 11.0; 11.0; 13.2; 12.3
PRIMARY
Lower Extremity Strength- Timed Stair Climb Test
3.7; 4.0; 4.2; 4.1; 3.6; 3.7
PRIMARY
Lower Extremity Mobility- Forward Step-down Test
13.2; 11.3; 10.8; 11.2; 15.4; 12.9
PRIMARY
Lower Extremity Mobility- 6-Minute Walk Test
24612; 23931; 23999; 23174; 24373; 24919
SECONDARY
Current Knee Pain
3.48; 3.42; 4.24; 3.98; 2.99; 2.78
SECONDARY
Knee Pain Following Performance Testing- 30-Second Chair Stand Test
2.9; 2.8; 3.9; 3.6; 2.9; 2.2
SECONDARY
Knee Pain Following Performance Testing- Stair Climb Test
2.7; 2.7; 3.5; 3.0; 2.6; 2.3
SECONDARY
Knee Pain Following Performance Testing- Forward Step Down Test
4.2; 4.2; 5.2; 5.3; 3.8; 3.2
SECONDARY
Knee Pain Following Performance Testing- 6-Minute Walk Test
3.2; 2.7; 4.5; 3.6; 3.3; 2.5

Summary

The overall objective of this project is to compare the three home-managed treatment regimens for PFPS: neuromuscular electrical stimulation (NMES), transcutaneous electrical nerve stimulation (TENS), and NMES combined with TENS to a standard home exercise program (HEP). Each of the three treatment arms will be supplemented by HEP and compared to a group receiving standard HEP alone. The central hypothesis is that the combination of NMES with TENS will show significantly greater improvements in muscle strength, mobility, pain, daily activity and quality of life (QOL) than HEP alone. The investigators are examining: 1) whether the three treatment regimens are significantly more efficacious than standard HEP alone in improving lower extremity muscle strength, physical activity, mobility, pain, and quality of life; 2) lower extremity muscle strength, physical activity, mobility, pain, and quality of life differ significantly across the 4 time periods; 3) is there an interaction between treatment and time in relation to lower extremity muscle strength, physical activity, mobility, pain, and quality of life.

Eligibility Criteria

Inclusion Criteria

The study will be open to all active duty personal who are:

  • diagnosed with knee pain, categorized as anterior or retropatellar in one or both knees;
  • self-reported difficulty performing at least two or more of the following activities associated with knee pain: prolonged sitting, stair climbing, running, jumping and repetitive movements such as kneeling or squatting or stooping;
  • military service member at the time of diagnosis;
  • age ≥18 and <45 years; and
  • ability to provide freely given informed consent.

Exclusion Criteria

Those who might be at risk of adverse outcomes from the study interventions will be excluded. This includes individuals with

  • Fracture or injury to external knee structures such that knee extension or flexion is impaired;
  • A significant co-morbid medical condition (such as severe hypertension, neurological disorder or pacemaker/defibrillator) in which NMES strength training or unsupervised exercise is contraindicated and would pose a safety threat or impair ability to participate;
  • Previous knee surgeries (i.e., tibiofemoral, patellofemoral) excluding knee arthroscopy;
  • Knee instability or recurrent patella dislocation or subluxation;
  • Inability or unwillingness to participate in a home exercise program or strengthening program;
  • Inability to speak and/or read English;
  • Reduced sensory perception in the lower extremities;
  • Pregnancy;
  • Vision impairment, where participant is classified as legally blind;
  • Unwillingness to accept random assignment; or
  • A score of 23 or greater on the Center for Epidemiological Studies-Depression scale (CES-D).
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02597673). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search